Molecular Templates, Inc.: restructuring charge — Molecular Templates board approves dissolution, expects no value for shareholders

Molecular Templates, Inc.

Board unanimously approved liquidation and wind-up subject to stockholder approval; no viable strategic alternatives found.
Company does not expect stockholders to receive any value for their shares in dissolution.
Reduction in force of substantially all employees; Phase 1 studies for MT-6402 and MT-8421 to be wound down.
Discussions with FDA on MT-0169 for autoimmune indications to continue; Rock Creek Advisors engaged.
Negligible costs expected for reduction in force; substantially complete in October 2024.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Molecular Templates, Inc. announced a restructuring with charges of negligible amount affecting substantially all of the Company’s employees (reduction in force of substantially all of the Company’s employees, other than key members of management).

Type: restructuring
Charge: negligible amount
Affected area: substantially all of the Company’s employees
Headcount: reduction in force of substantially all of the Company’s employees, other than key members of management

Exact text from the filing

On October 11, 2024, the Board approved a reduction in force of substantially all of the Company’s employees, other than key members of management necessary to implement the wind up and support the efforts to maximize the value of the business and its assets. The Company estimates that it will incur a negligible amount of costs in connection with the reduction in force, primarily consisting of legal fees and other related termination costs.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-24-236770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.